Search results
Your search for ���������������,���������������������������������������:kn39��� returned no results
Showing 361 to 375 of 728 results for ���������������,���������������������������������������:know���
Showing 361 to 375 of 728 results for ���������������,���������������������������������������:know���
your symptoms might not improve and you might get new symptoms. You will know that all the mesh has been removed (if this is possible),...
your symptoms might not improve and you might get new symptoms. You will know that all the mesh has been removed (if this is possible),...
Heart valve disease presenting in adults: investigation and management (NG208)
This guideline covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
NICE says paperclip-sized sensor could help thousands monitor heart condition from home
A wireless sensor the size of a paperclip could transform care for people living with chronic heart failure, enabling them to monitor their condition daily from home and catch warning signs before they become emergencies, NICE has said.
This quality standard covers the recognition, diagnosis and early management of suspected sepsis in people over 16 who are not or have not recently been pregnant. It describes high-quality care in priority areas for improvement.
View quality statements for QS213Show all sections
Sections for QS213
- Quality statements
- Quality statement 1: Assessment in acute settings
- Quality statement 2: Assessment outside acute settings
- Quality statement 3: Urgent assessment and antibiotic treatment for people at high risk
- Quality statement 4: Intravenous fluids
- Quality statement 5: Escalation of care
- Quality statement 6: Information for people whose condition is managed outside acute hospital settings
- Update information
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Evidence-based recommendations on selpercatinib (Retsevmo) for untreated RET fusion-positive advanced non-small-cell lung cancer in adults.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies.
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)
Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults.
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)
Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia in adults.
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.